Literature DB >> 11377601

Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England.

P Sasieni1, J Adams.   

Abstract

BACKGROUND: A recent analysis showed little or no effect of screening on the incidence of adenocarcinoma of the cervix between 1971 and 1992. We have used additional data on cancers diagnosed in 1993-94 in England and up to 1997 in five English cancer registries to investigate more recent trends.
METHODS: After inputing the number of adenocarcinomas in women with unknown histology, we fitted an age-cohort model to 8062 adenocarcinomas of the cervix diagnosed in England between 1971 and 1987. Predictions from this model were applied to the more recent data on 5854 cases. Residual effects were plotted against year of diagnosis in each of four age-groups.
FINDINGS: We estimated the underlying risk of cervical adenocarcinoma to be 14 times (95% CI 11-19) greater in women born in the early 1960s than in cohorts born before 1935. An age-cohort model fitted the data for England well up to 1987, but substantially overestimated the numbers of adenocarcinomas in young women from 1990 onwards. In 1996-97 the incidence rate in women aged 25-54 years was less than 40% of that predicted from the age-cohort model.
INTERPRETATION: The substantial increase in cervical adenocarcinoma in recent years is largely a birth-cohort effect presumably associated with greater exposure to human papillomavirus after the sexual revolution in the 1960s. The relative decline in younger women observed in more recent years suggests an effect of cervical screening.

Entities:  

Mesh:

Year:  2001        PMID: 11377601     DOI: 10.1016/S0140-6736(00)04646-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

Authors:  S Bulk; F J Van Kemenade; L Rozendaal; C J L M Meijer
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

2.  Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma.

Authors:  Yanli Xiong; Jia Liu; Shu Chen; Qian Zhou; Wenjing Xu; Chen Tang; Yonghong Chen; Mei Yang; Xin Lei
Journal:  Med Oncol       Date:  2015-08-14       Impact factor: 3.064

3.  Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis.

Authors:  Lea A Moukarzel; Ana M Angarita; Christopher VandenBussche; Anne Rositch; Carol B Thompson; Amanda N Fader; Kimberly Levinson
Journal:  J Low Genit Tract Dis       Date:  2017-04       Impact factor: 1.925

4.  The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas.

Authors:  S Andersson; A-C Hellström; Zhi-Ping Ren; E Wilander
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 5.  Vaccines for cervical cancer.

Authors:  C M Lowndes
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

6.  Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype.

Authors:  Yasuki Kusanagi; Atsumi Kojima; Yoshiki Mikami; Takako Kiyokawa; Tamotsu Sudo; Satoshi Yamaguchi; Ryuichiro Nishimura
Journal:  Am J Pathol       Date:  2010-09-09       Impact factor: 4.307

7.  Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas.

Authors:  Dieuwke L Marvin; Vivian M Spaans; Cor D de Kroon; Roderick C Slieker; Maryam Khelil; Peter Ten Dijke; Laila Ritsma; Ekaterina S Jordanova
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

8.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.

Authors:  J-Y Park; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.

Authors:  Yoshihisa Arakaki; Takuro Ariga; Joichi Heianna; Yuko Shimoji; Tadaharu Nakasone; Yusuke Taira; Tomoko Nakamoto; Takuma Ooyama; Wataru Kudaka; Itomi Kaneshima; Kumiko Nishihira; Keiko Mekaru; Yoichi Aoki
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

10.  Cervical cancer in the screening era: who fell victim in spite of successful screening programs?

Authors:  B Folke Pettersson; Kristina Hellman; Roxane Vaziri; Sonia Andersson; Ann-Cathrin Hellström
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.